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INTRODUCTION
Glycocalyx, the sugar protein coating of the vascular 
endothelium, forms an integral part of the vascular 
barrier and contributes to 2% of the plasma volume 
[Figure 1a]. The endothelial glycocalyx layer (EGL) 
plays a pivotal role in body fluid homeostasis, 
modulation of inflammatory reactions, adhesion of 
platelets and leukocytes and is breached in conditions 
such as trauma, sepsis, diabetes, electrolyte imbalance, 
surgery and overzealous fluid management.[1,2]
Intravenous (IV) fluid administration plays an integral 
part in the management of a patient. As described 
by Malbrain et al.,[3] there are four major indications 
for IV fluid administration, namely, resuscitation, 
maintenance and supplementation of fluid and 
electrolytes, as a carrier for IV drugs and for parenteral 
nutrition. Improper administration of IV fluid 
can cause serious alteration of normal physiology 
including damage of the vital EGL layer.
This review was undertaken to describe the structure, 
physiology and functional basis of the EGL, its relevance 
in body fluid homeostasis and IV fluid management in 
various clinical and pathological conditions.
A thorough literature search was done from 
inception to September 2018 using databases/search 
engines (Medline, Embase, Scopus, PubMed, Google 
Scholar and websites of National Societies for IV 
fluid management). The articles were manually 
searched by the authors for cross-referencing. All 
the articles published in English were searched. 
We used the following keywords “endothelial 
glycocalyx,” “intravenous fluid therapy,” “fluid 
homeostasis,” “Starling equation,” “Revised 
Starling equation,” “Liver failure,” “Nephrotic 
syndrome,” “Heart failure,” “Oedema,” “Albumin,” 
“Sepsis” and “ARDS.” The relevant information 
pertinent to the role of EGL in various conditions 
were included.
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ABSTRACT
Endothelial glycocalyx layer (EGL) coating the luminal surface of vascular endothelium plays an 
essential role in maintaining the normal fluid homeostasis of the body. This highly fragile layer 
can be damaged by a number of pathophysiological conditions and interventions. Disease state 
management should be directed to maintain EGL integrity to improve patient’s outcome. When 
intravenous (IV) fluids are used, appropriate type, rate and amount of fluid should be determined 
by the pathophysiology of the condition and measures to maintain the integrity of the EGL. This 
review depicts the structure and function of the EGL, its alteration in common pathological states 
and the rationale of IV fluid management to preserve EGL in such conditions.
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STRUCTURE OF EGL
The composition of the EGL varies according to the 
microenvironment. The most prominent constituents 
of EGL are proteoglycan, glycoproteins and 
glycosaminoglycans (GAGs) along with other soluble 
components such as proteins [primarily albumin 
along with antithrombin-III (ATIII), apolipoproteins], 
hormones, enzymes such as extracellular superoxide 
dismutase-3 (SOD3), angiotensin-converting enzyme, 
growth factors, chemokines and adhesion molecules 
(selectins and integrins)[1] [Figure 1b].
The central protein core is made up of proteoglycans 
to which the negatively charged highly sulphated 
GAGs remain attached. Syndecan and glypicans are 
the major proteoglycans having a firm connection to 
the cell membrane forming the backbone of the EGL. 
The other proteoglycans such as mimecan, perlecan 
and biglycan are secreted later and contribute to the 
soluble portion of the glycocalyx.[1]
There are five types of GAG chains, namely, heparan 
sulphate, chondroitin sulphate, dermatan sulphate, 
keratan sulphate and hyaluronan (or hyaluronic acid). 
Hyaluronic acid is the only nonsulphated, uncharged 
GAG not usually attached to any core protein. It is 
usually attached to cell surface proteins (CD44)[4] and 
forms a viscous solution by exhibiting water-retaining 
characteristics. Glycocalyx forms a meshwork in 
which proteins and soluble GAGs get attached. It has 
a fixed part which remains attached to the endothelial 
layer and a dynamic part, which is in equilibrium 
with circulating blood volume. Proteins <70 kDa such 
as extracellular SOD, ATIII and albumin are present 
in the dynamic part of the EGL layer which have 
variable structure and composition [Figure 1b]. The 
adhesion molecules such as platelet endothelial cell 
adhesion molecule (PECAM), vascular cell adhesion 
molecule (VCAM) and intercellular adhesion 
molecule (ICAM) are also embedded within the 
structures.
The presence of sulphated GAGs renders a negative 
charge to the glycocalyx. Hence, its interaction varies 
with varying charge of molecules and also acts as a 
barrier repelling the negatively charged molecules 
like red blood cell (RBC), white blood cell (WBC) 
and platelets, forming a “cell exclusion zone.” 
The layer also acts as a sieve, restricting passage 
of molecules >70 kDa. However, the amphoteric 
nature of albumin and size of 67kDa helps it to bind 
tightly to the glycocalyx. Some albumin even leaks 
through the glycoprotein layers. This attachment of 
albumin reduces the hydraulic conductivity across 
vasculature.[1]
There are several techniques to visualise the vital EGL 
layer both in vivo and in vitro. In vitro visualisation 
started with transmission electron microscopy which 
gained accuracy over decades by development of 
glycocalyx-sparing fixation techniques. In vivo 
techniques comprise confocal laser scanning 
microscopy which allows 3D reconstruction of the 
EGL. However, its less penetration makes it less useful 
in visualising EGL of large vessels. Two-photon laser 
scanning microscopy is one of the most promising 
technique allowing fairly accurate EGL visualisation 
both in vivo and in vitro.[5] Real-time visualisation by 
handheld videomicroscopy is the latest trend. Based 
on the mean distance between RBC and vessel wall, an 
assessment of EGL thickness is calculated by post hoc 
software analysis.[6]
FUNCTIONAL IMPORTANCE OF GLYCOCALYX
The negatively charged GAGs are arranged like branches 
covering the glycoprotein receptors[1,7] [Figure 2]. The 
Figure 1: Structure of endothelial glycocalyx (EGL). (a) 2% of the non‑circulating portion of the intravascular volume formed by EGL. RBC, WBC 
and platelets are excluded from the non‑circulating EGL, which is in dynamic equilibrium with plasma. (b) Structure and various constituents of 
EGL layer. RBC – Red Blood Cell, WBC – White Blood Cell, Alb – Albumin, SOD – Superoxide dismutase, ATIII – Antithrombin III
ba
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adhesion receptors are therefore protected by the 
GAG branches. These receptors are mostly of two 
types: selectins and immunoglobulins. Histamine, 
thrombin, interleukins and tumor necrosis factor bind 
to the selectin while immunoglobulins have adhesive 
molecules for ICAM, VCAM and PECAM.
External or internal insults like loss of flow 
(thrombosis, arteriosclerosis), inflammation (systemic 
inflammatory response, diabetes, trauma, sepsis) 
and rapid administration of fluid can damage the 
glycocalyx. This results in exposure of the receptors 
of the glycocalyx to combine with the noxious ligands 
that result in signal transduction. Hence, damage to 
glycocalyx significantly affects the microcirculation.[8]
REVISED STARLING PRINCIPLE
As per Starling’s model,[9] the net force at the 
arteriolar end of the capillaries pushes fluid out 
as a result of high hydrostatic pressure and at the 
venous end fluid re-enters the vessels because of 
osmotic attraction. The Starling equation reads as 
follows: Jv = Kf ([Pc	−	Pi] – σ [πc	−	πi]), where Jv is 
the net fluid movement between compartments and 
[Pc	−	Pi]	−	σ [πc −	πi] is the net driving force, Pc is 
the capillary hydrostatic pressure, Pi is the interstitial 
hydrostatic pressure, πc is the capillary oncotic 
pressure, πi is the interstitial oncotic pressure, Kf is 
the filtration coefficient – a proportionality constant, 
and σ is the reflection coefficient). Starling stated that 
these forces are balanced [Figure 3a].
However, it was later demonstrated that the effect of 
πi on transvascular fluid exchange is significantly less 
than predicted by the standard Starling’s equation 
due to the presence of EGL.[10] Hence, the revised 
Starling’s principle considers the presence of EGL 
which comprises adsorbed albumin molecules and 
exerts a significant osmotic pressure than interstitium 
as was thought earlier. Just below the EGL, there is an 
empty subglycoclyx space[11] [Figure 4]. Albumin is 
transported across the cell membrane by the process 
of endocytosis, whereas the circulating albumin in 
the blood is adsorbed over the GAG side chains and 
contributes to the soluble layer of the EGL. The zone 
below the soluble portion of EGL is an acellular zone 
also known as the red cell exclusion zone. The adsorbed 
albumin in the soluble portion of EGL contributes to 
60% of colloid osmotic pressure (COP) of the total 
intravascular COP that is higher than the circulating 
plasma. Hence, an osmotic gradient is created 
between the EGL and subglycocalyx zone (protein-free 
zone in the intercellular cleft between cells below 
the glycocalyx). The revised Starling’s equation 
incorporates πg (glycocalyx oncotic pressure) instead 
of πi, and is stated as Jv = Kf ([Pc	−	Pi]	−	σ [πc	−	πg]) 
[Figure 3b].
Hence, the oncotic pressure difference is not built up 
between the intravascular and the interstitial tissue 
spaces, but within a small protein-free zone beneath 
the glycocalyx surface layer (subglycocalyx space). 
The capillary hydrostatic pressure and subglycocalyx 
Figure 2: Protective mechanism of EGL. Adhesion molecules remain 
embedded in EGL layer refraining adhesion of endothelial cells and 
inflammatory mediators. Gp – Glycoprotein, Pg – Proteoglycan, 
ICAM – Intercellular Adhesion Molecule, VCAM – Vascular Cell 
Adhesion Molecule, PECAM – Platelet Endothelial Cell Adhesion 
Molecule
Figure 3: (a) Original Starling’s equation Jv – Kf ([Pc – Pi] – σ [πc – πi]. Fluid pushed out at the arteriolar end equals fluid reabsorbed at the 
venular end. (b) Modified Starling’s equation taking EGL layer into consideration Jv – Kf ([Pc – Pi] – σ [πc – πg]). Lymph plays a major role in 
returning fluid back into the circulation
ba
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pressure help draw the fluid in the interstitial space. 
This fluid that filters out forms the “ultrafiltrate.” In the 
interstitium, the hydrostatic and the osmotic pressure 
are much low, hence negligible fluid goes back to the 
capillaries at the venous end to cause any venous 
reabsorption. The lymphatics play all important role to 
remove the excess fluid which comes to the interstitial 
space and is put back into circulation [Figure 4]. The 
revised Starling’s equation states that (a) intravascular 
volume comprises circulating RBC volume, plasma 
volume and glycocalyx volume instead of only plasma 
and cellular elements, (b) ultrafiltrate is produced 
due to filtration across glycocalyx and no venous 
reabsorption occurs at the venous end and (c) lymph 
forms the major route for return of fluid into circulation 
as it removes the fluid from the interstitial space.
EGL AND FLUID THERAPY
IV fluid should be administered when the fluid or 
electrolyte needs cannot be met orally or enterally or 
IV fluid has to be given as a medium for giving drugs. 
As per the National Institute of Health and Care 
Excellence (NICE) guidelines,[12] 5 Rs (Resuscitation, 
Routine maintenance, Replacement, Redistribution and 
Reassessment) should be kept in mind while prescribing 
IV fluids and early de-escalation is warranted.
Crystalloids are solution of inorganic ions 
and small organic molecules in water and are 
divided according to tonicity in to iso, hypo or 
hypertonic solutions. Overadministration of acidic 
crystalloids with strong ion difference like normal 
saline (NS) with chloride of 153 mmol/L can lead 
to hyperchloremic metabolic acidosis and damage 
the EGL and result in acute kidney injury (AKI) and 
impaired clotting functions[13] [Figure 5a]. Rapid NS 
administration can initiate excess plasmin activity 
and auto-heparinisation from EGL shedding resulting 
in diffuse coagulopathy specially in a background 
of trauma or sepsis.[14,15] Balanced crystalloids like 
lactated Ringer (Cl 109 mmol/L) and plasmalyte 
A (Cl 98 mmol/L) are more physiological and are similar 
in composition to human plasma [Figure 5b]. They are 
more compatible with EGL. Large randomised clinical 
trials like SMART[16] and SALTED[17] in both critically 
ill and noncritically ill patients have shown that major 
adverse renal events (AKI and requirement of renal 
Figure 4: The oncotic pressure difference is build up between the 
adsorbed albumin in the soluble EGL layer a small protein free 
zone (subglycocalyx space) leading to the revised Starling’s equation
Figure 5: (a) Distribution and excretion of normal saline (0.9% NS) after intravenous administration. The high chloride load is above physiological 
limit and can contribute to hyperchloremic metabolic acidosis. (b) Distribution, metabolism and excretion of balanced salt solution (Ringers lactate 
and Plasmalyte A) with intact EGL layer. (c) Distribution and excretion of balanced salt solution (Ringers lactate and Plasmalyte A) with damaged 
EGL layer leading to edema formation. ECF – Extracellular fluid, RL – Ringer’s Lactate, PL – Plasmalyte A, Cl‑ – Chloride, HCO3— – Bicarbonate
c
ba
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replacement therapy) are less with administration of 
balanced salt solution having low chloride content 
(<110 mmol/L) compared with NS. However, balanced 
crystalloids are hypotonic compared with extracellular 
fluid and are associated with metabolic alkalosis, hence 
they are not completely harmless. With damaged EGL, 
the distribution of the balanced salt solution changes 
contributing to interstitial oedema [Figure 5c].
Colloids due to their large molecular size are expected to 
stay in the intravascular space for a longer time thereby 
creating an increase in oncotic pressure. Colloids 
commonly used are natural (albumin) or artificial 
(gelatin, dextran and hydroxy ethyl starch). Albumin 
has lower molecular size (67 kDa) and is part of soluble 
part of EGL.[18] Presence of hypoalbuminaemia has 
shown to contribute to increased EGL damage in trauma 
and sepsis along with increased leakage of albumin into 
the interstitial space when compared with patients with 
normal albumin levels. Albumin (5%) helps maintain 
the integrity of the EGL and is advised as an early 
modality of treatment in trauma with the exception 
of traumatic brain injury.[19] Artificial/semisynthetic 
colloid administration is associated with increased 
incidence of anaphylactoid reactions, coagulopathy 
and AKI. Newer generation 6% hydroxy ethyl 
starch (HES) (130/0.42) was presumed to offer a wider 
safety and efficacy range. However, Scandinavian[20] 
and CHEST[21] trials have demonstrated increased 
long-term mortality and AKI.
Revised Starling equation’s implication
At subnormal capillary pressure, infusion of colloid 
solution preserves plasma COP, raises capillary 
pressure and increases Jv. While infusion of crystalloids 
also raises capillary pressure, it lowers COP and thus 
increases Jv more than the same colloid solution 
volume. At subnormal capillary pressure, infusion of 
crystalloid is therefore a better choice as first line of 
fluid management [Figure 6a].
Inflammation, trauma, shock (hypovolemic, 
septic), hyperglycemia, ischaemia and reperfusion, 
electrolyte imbalance and iatrogenic causes like rapid 
administration of fluids and surgery cause damage to 
the EGL. Ageing, lack of moderate exercise, high-sugar 
diet and smoking are also important predisposing 
factors that contribute to EGL damage.
EGL takes 6–8 h to regenerate under normal 
physiological conditions. In pathological conditions, 
the regeneration time varies from hours to days 
depending on the extent of the ongoing insult and the 
volume of glycocalyx damaged. In experimental model 
of enzymatic degradation, EGL takes 5–7 days or more 
to attain the previous thickness.[22]
Rapid administration of IV fluid can cause damage 
to the EGL in healthy volunteers.[23] However, in 
hypovolemic or septic shock, IV fluids should be 
administered through large veins via large bore cannula 
to avoid fluid jet to prevent damage to the delicate EGL 
grid. Current evidence suggests that blood products 
and IV fluids more than 500 mL should be warmed 
to 37°C which helps in maintaining the core body 
temperature and protects the EGL.[24]
EGL is destroyed by large volume of fluids or 
hypervolemia. Atrial natriuretic peptide released 
from the stretching of atria is considered to be one of 
the triggers for EGL destruction. NICE guidelines[12] 
recommend routine maintenance of 25–30 mL/kg/day 
of water, 1 mmol/kg/day of potassium, sodium and 
chloride and 50–100 g/day of glucose in patients 
requiring IV fluids. Addition of glucose is to limit 
starvation ketoacidosis. However, in old and frail 
patients with renal impairment and cardiac failure, the 
total amount should be restricted to 20–25 mL/kg/day. 
Caution should be exercised in obesity, where the ideal 
body weight should be considered and IV maintenance 
fluid should not exceed 3 L/day. Replacement fluids 
should also be governed by the composition and 
Figure 6: (a) Distribution of various commonly used fluids (crystalloids 
and colloids) in different body compartments. (b) Composition of 
various transcellular fluids in human body and the type of replacement 
fluids to be used depending on the type of fluid loss. RL – Ringer’s 
Lactate, PL – Plasmalyte A, NS – Normal Saline, D5W – 5% Dextrose, 
Na+ – Sodium, K+ – Potassium, Cl‑ – Chloride, HCO3‑ – Bicarbonate
b
a
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amount of fluid loss from different sources (sweat, 
gastric, bile, pancreas, ileum, colon) [Figure 6b].
Recent meta-analysis[25] suggests that prognosis with 
restrictive/goal-directed fluid therapy is better compared 
with liberal fluid administration. The damage of EGL 
by liberal fluid administration increased leakiness of 
the endothelium. This extravasation of fluid into the 
interstitium increases inflammation, wound infection 
and derangement in coagulation function resulting in 
increased morbidity and mortality. However, clinical 
trial recommending liberal fluid over restricted in major 
abdominal surgeries causing higher rate of AKI in the 
restrictive fluid group is also a concern.[26] Therefore, 
calculating the appropriate amount of fluid in critical 
situation can be tricky and fluid responsiveness of the 
patient should be assessed specially by dynamic tests 
which are more sensitive. These tests are based on the 
principle of inducing short-term changes in cardiac 
preload, using heart–lung interactions, by the infusion 
of small volumes of fluid or by passive leg raise and 
to observe the resulting effect on cardiac output. The 
passive leg raise is an evidence-based most commonly 
used bedside test to detect fluid responsiveness of a 
patient.
Overzealous rapid administration of IV fluids can 
damage the EGL. Preloading in the presence of 
normovolemia before induction of general or 
neuraxial anaesthesia to combat sudden decrease in 
preload is not justified. Preloading neither decreases 
the incidence of vasopressor use nor hypotension but 
increases the morbidity due to destruction of EGL.[27] 
Rehm M et al.[2] in their study on isolated guinea pig 
heart showed that unless the EGL is destroyed by 
enzymes, the endothelial leakiness is not that profound 
even after ischaemic insults or treatment with heparin. 
The endothelium gets leaky with the extravasation of 
fluid only when the protective EGL is destroyed. The 
study also showed that infusion of 6% HES decreased 
coronary perfusion pressure significantly, whereas 
albumin and 0.9% NS had minimal effect.
EGL AND CLINICAL PATHOPHYSIOLOGY
Oedema is the accumulation of fluid in the interstitium 
with an increase in interstitial compliance. Tissue 
oedema occurs when the rate of transudation of fluid 
in the interstitial space from the capillaries surpasses 
the maximum lymphatic drainage. The mechanism of 
oedema formation is different in various pathological 
conditions.
Heart failure
Intact EGL has the ability to buffer an increase in 
total body sodium without water retention. As a 
result of heart failure, there is excessive sodium 
accumulation in the body both from renal retention 
and EGL degradation. The process of oedema in 
acute and chronic heart failure is different. In acute 
heart failure (AHF), redistribution of fluid occurs 
from splanchnic and peripheral circulation due to 
sympathetic activation rather than actual increase 
in intravascular volume which otherwise occurs in 
chronic heart failure. Hence, in accordance with 
Starling forces an increase in transcapillary hydrostatic 
pressure and a decrease in transcapillary oncotic 
pressure gradient cause the fluid to extravasate into 
the interstitium resulting in an increase in interstitial 
pressure due to excessive fluid accummulation that 
compromises the lymphyatic drainage. Diuretics, 
ubiquitously used as a first-line treatment of heart 
failure, decreases capillary hydrostatic pressure and 
thereby decreases Jv making lymphatic drainage from 
the interstitium more effective and reducing oedema. 
However as the protective EGL buffer is destroyed, a 
large amount of sodium escapes renal clearance and 
continues to contribute to oedema formation[6] and 
diuretics alone are not effective. In AHF characterised 
by volume redistribution, diuretics administered as 
the first line of treatment can cause a decrease in left 
ventricular function, an increase in ventricular filling 
pressure and systemic vascular resistance by activating 
renin–angiotensin–aldosterone pathway and thereby 
a decrease in glomerular filtration. A combination of 
vasodilators like nitrates and hydralazine, positive 
pressure ventilation and ionotropes might be beneficial 
in AHF to combat the sudden redistribution of fluid. 
However, for chronic heart failure where there is 
actual fluid retention, sodium restriction to less than 
2 g/day, angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers, angiotensin receptor 
neprilysin inhibitor, beta blockers and aldosterone 
antagonists along with diuretics can improve oedema 
and prevent cardiac remodelling.[28]
Nephrotic syndrome
The renal basement membrane has fenestrated 
continuous capillaries and scanty EGL. The 
fenestrations are normally around 65 nm in size which 
reduces to 15 nm due to the overlaying of glycocalyx 
on the fenestrations. The effective filtration pore size 
at the level of podocytes is only 6 nm contributed 
by the filtration slit diaphragm. Thus, with intact 
basement membrane, albumin is not found in the 
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tubular fluid and its presence depicts a breach in 
capillary permeablility. In nephrotic syndrome, 
oedema begins to develop before proteinuria and a 
decrease in serum albumin is observed. An increase in 
glycocalyx degradation product (syndecan-1) in blood 
is observed in early stages of nephrotic syndrome with 
preserved renal function.
The mechanism of oedema formation in nephrotic 
syndrome is complex. Decrease serum albumin, 
intravascular volume status, neurohormonal factors 
and an integrating mechanism of sodium retention 
irrespective of intravascular volume due to activation 
of epithelial sodium channels (ENaC) are thought 
to be the contributing factors.[29] The mechanism 
of oedema formation in nephrotic syndrome has 
been described by two hypotheses, the underfill 
and the overfill hypotheses. The underfill hypothesis 
states that a decrease in plasma oncotic pressure 
due to hypoalbuminaemia increases the Jv and 
causes extravasation of fluid in the interstitial space 
causing oedema. The intravascular volume loss is 
sensed as hypovolemia and resultant activation 
of renin–angiotensin–aldosterone system causing 
secondary sodium retention. The overfill hypothesis 
states it is the primary renal sodium retention that 
results in oedema. Albumin can be considered as 
a modality of treatment if serum albumin is below 
2 g/dL, since it helps increase the plasma oncotic 
pressure. Angiotensin-converting enzyme inhibitors 
and angiotensin II receptor blockers reduce the amount 
of protein release in urine and help preserve plasma 
oncotic pressure in nephrotic syndrome. Diuretics 
increase the urine output by mobilising the fluid from 
the intravascular space thereby reducing the Jv and 
resulting in a decrease in Pi. The initial overburdened 
lymphatics in the interstitial space because of high 
Pi can now effectively drain the accumulated fluid 
in the interstitium. Corticosteroids are useful, since 
they help in decreasing the inflammation and prevent 
disease progression.[29]
Liver cirrhosis
In cirrhosis of liver, overexpression of Aplein (APLN) 
receptors activates hepatic stellate cells leading 
to tissue remodelling by chronic inflammation, 
neo-angiogenesis and fibrogenesis.[30] This actively 
damages the liver sinusoidal endothelial cells and 
completely disrupts the architecture of the liver. 
Fibrosis of the liver slows down the normal blood 
flow through liver and thus increases pressure in 
the portal vein. An increase in venous hydrostatic 
pressure increases Jv and causes extravasation of fluid 
in the interstitial space, causing oedema and ascites. 
The fibrosis decreases functional hepatic units, 
hampering the synthetic function of liver. This leads to 
hypoalbuminaemia since synthesis of albumin is one 
of the most important functions of liver. A decrease in 
plasma albumin decreases plasma oncotic pressure, 
thereby increasing Jv and contributing to the formation 
of oedema in cirrhosis. The treatment of oedema in 
cirrhosis is directed towards minimising portal venous 
pressure as well as increasing the plasma oncotic 
pressure. Maintaining negative sodium balance, 
administering diuretics, beta blockers, paracentesis 
and albumin infusion help in reducing the oedema in 
such situation.[30]
Sepsis and EGL
Sepsis damages the delicate EGL by directly altering 
its anionic charge and geometry and by increasing 
the interendothelial gaps. Expression of endothelial 
receptor adhesion molecules (ICAM 1, PECAM 1) 
increases in EGL due to proinflammatory and actute 
inflammatory mediators. These changes cause 
leucocyte activation and promote leukocyte rolling, 
adherence and migration into the interstitium by 
inflicting direct damage to the vascular endothelium. 
As a result, the vascular permeability increases 
causing fluid and albumin to shift to the interstitial 
space causing generalised oedema. The inflammatory 
mediators result in loss of vascular tone, peripheral 
pooling of blood and degradation of heparan 
sulphate, one of the component of EGL giving rise to a 
procoagulant state.
HOUR-1 sepsis bundle recommends administration 
of 30 mL/kg of crystalloids to correct hypotension and 
lactate more than 4 mmol/L.[31] FEAST trial[32] comparing 
40 mL/kg NS or 4% albumin volume resuscitation in 
septic children had to stop midway due to increased 
mortality caused by overzealous fluid resuscitation. 
Buffered isotonic crystalloids are recommended, but 
administration of large volumes should be avoided. IV 
fluid intervention helps improve cardiac output, organ 
perfusion and eventually tissue oxygenation, but the 
effect is transient due to leakiness and loss of retaining 
capacity of the damaged endothelium. Therefore, after 
the initial fluid resuscitation, early use of vasopressors 
to	 keep	 mean	 arterial	 pressure	 ≥65	 mmHg	 by	
increasing the stressed volume in the venous 
circulation is recommended. Vasopressors augment 
the mean systemic filling pressure, cardiac output and 
perfusion pressure to the vital organs.
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Pulmonary vasculature and EGL
The EGL in the pulmonary vasculature is thicker than 
the systemic vasculature indicating its significant role 
in maintaining normal pulmonary physiology. EGL 
plays a major role in mechanotrasduction and vascular 
permeability. Breech in the integrity of EGL can result 
in interstitial oedema and hypoxia. EGL serves as a 
barrier to neutrophils, fluid and protein extravasation. 
In addition it also plays a role in nitric oxide signalling 
thereby modifying endothelial permeability. Acute 
lung injury and acute respiratory distress syndrome 
can result as a consequence of EGL disruption. 
Detection of EGL degradation product in blood may 
serve as an indicator of impending pulmonary damage 
and its restoration by substances like clinically 
therapeutic dose of heparin having anti-inflammatory 
properties can act as a promising therapeutic measure 
in critically ill patients.[33]
PROTECTION OF EGL
EGL protection is gaining interest as a therapeutic 
target in modern medicine. Established therapy like 
blood glucose control and corticosteroids help in 
protection of the EGL.[34] Some of the experimental 
therapies to protect the EGL are showing promising 
results. Attenuating the inflammatory damage of EGL 
by inhibition of proinflammatory cytokines is one 
of the suggested options. Etanercept, which treats 
autoimmune diseases by inhibiting tumor necrosis 
factor (TNF-α), has been tried to preserve EGL 
function.[35] ATIII has shown its efficacy in blocking 
the activation of the transcription factor, nuclear 
factor kB which is the regulator of innate and adaptive 
immune responses, and plays an important role in 
allergic airway diseases.[34] Etanercept and ATIII block 
inflammatory cytokines like interleukin-6, TNF-α and 
tissue factor genes and help protect delicate EGL. 
Statins have shown to protect EGL by combating free 
radical (oxidised lipoprotein) induced injury to the 
endothelium and decreasing inflammatory reactants 
like C-reactive proteins.[36] However, there is lack of 
evidence in favour of their use especially in patients 
who are statin-naive and have chronic kidney 
disease, where studies have shown to increase the 
incidence of further renal derangement.[37] Sevoflurane 
protects EGL degradation by both preconditioning 
and early post conditioning. Sevoflurane attenuates 
liposomal cathepsin B release independent of mast 
cell degranulation and looks promising in protecting 
the EGL.[38] Neferine, a bisbenzylisoquinoline plant 
alkaloid, probably has a promising role in protecting the 
EGL by suppressing the production of mitochondrial 
ROS.[39] Sulodexide is a highly purified mixture of GAGs 
composed of  low molecular weight heparin (80%) 
and dermatan sulphate (20%) prepared from porcine 
intestinal mucosa.[40] There is sufficient evidence that 
sulodexide helps in regeneration of glycocalyx layer 
particularly in sepsis.[40] EGL degradation markers like 
syndecan-1, heparan sulphates, heparanase, endocan, 
hyaluronic acid, chondroitin and angiopoietins are 
potential markers of glycocalyx damage and can be 
used as a diagnostic tool for endothelial dysfunction 
and sepsis severity.
SUMMARY
EGL lining nonfenestrated capillaries plays an 
important role in body fluid homeostasis. The modified 
Starling’s equation incorporates the importance of 
EGL and subendothelial glycocalyx space in governing 
transcapillary forces responsible for ultrafiltration 
across the endothelial cell layer. Hence, damage to 
the EGL manifests as oedema in various pathological 
conditions (heart failure, liver cirrhosis, nephrotic 
syndrome, sepsis and trauma), which reflects the 
state of abnormal microcirculation. Therapy directed 
towards preserving EGL and taking measure towards 
its regeneration are currently the corner stone of 
management of disease states. Fluid management in 
these conditions is an ubiquitous intervention and 
choosing the right amount and type of fluid is essential 
to improve the quality of patient care.
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